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DICER1 syndrome (OMIM 606241, 601200) is a rare autosomal dominant familial tumor predisposition disorder with a heterozygous
DICER1 germline mutation. The most common tumor seen clinically is the pleuropulmonary blastoma (PPB), a lung neoplasm of
early childhood which is classiﬁed on its morphologic features into four types (IR, I, II and III) with tumor progression over time
within the ﬁrst 4–5 years of life from the prognostically favorable cystic type I to the unfavorable solid type III. Following the initial
report of PPB, its association with other cystic neoplasms was demonstrated in family studies. The detection of the germline
mutation in DICER1 provided the opportunity to identify and continue to recognize a number seemingly unrelated extrapulmonary
neoplasms: Sertoli-Leydig cell tumor, gynandroblastoma, embryonal rhabdomyosarcomas of the cervix and other sites,
multinodular goiter, differentiated and poorly differentiated thyroid carcinoma, cervical-thyroid teratoma, cystic nephromaanaplastic sarcoma of kidney, nasal chondromesenchymal hamartoma, intestinal juvenile-like hamartomatous polyp, ciliary body
medulloepithelioma, pituitary blastoma, pineoblastoma, primary central nervous system sarcoma, embryonal tumor with
multilayered rosettes-like cerebellar tumor, PPB-like peritoneal sarcoma, DICER1-associated presacral malignant teratoid neoplasm
and other non-neoplastic associations. Each of these neoplasms is characterized by a second somatic mutation in DICER1. In this
review, we have summarized the salient clinicopathologic aspects of these tumors whose histopathologic features have several
overlapping morphologic attributes particularly the primitive mesenchyme often with rhabdomyoblastic and chondroid
differentiation and an uncommitted spindle cell pattern. Several of these tumors have an initial cystic stage from which there is
progression to a high grade, complex patterned neoplasm. These pathologic ﬁndings in the appropriate clinical setting should
serve to alert the pathologist to the possibility of a DICER1-associated neoplasm and initiate appropriate testing on the neoplasm
and to alert the clinician about the concern for a DICER1 mutation.
Modern Pathology (2022) 35:4–22; https://doi.org/10.1038/s41379-021-00905-8

INTRODUCTION
DICER1 gene is located on chromosome 14q32.13 and plays a
crucial role in the control of protein translation; its product, dicer
protein, is a ribonuclease (RNase) III endoribonuclease which is
essential for the production of microRNAs (miRNA) which are
formed by the cleavage of pre-miRNA or double-stranded RNA1–4.
RNase III contains two domains, IIIa and IIIb which cleave 3p
miRNA and 5p miRNA from the 3′ and 5′ pre-miRNA, respectively.
These cleavages require magnesium ions at the interface between
the IIIa and IIIb domains and the miRNA; this magnesium
dependent catalytic processing occurs at speciﬁc residues,
E1320, E1564, E1813 and D17092–4. miRNA has a pivotal role in
regulating the expression of over 30% of protein-coding genes by
its interaction with mRNA5. Given the impact of DICER1 in posttranslational events, it is not entirely surprising that functional
DICER1 is essential for vertebrate development as evidenced by
developmental arrest and death of the embryo when both alleles
are lost6,7. Conceptually, DICER1 can be regarded as either a tumor

suppressor gene due to loss-of-function mutations or an
oncogene due to gain-of-function mutations; it is thought to
function as a haploinsufﬁcient tumor suppressor gene with the
loss of one allele leading to tumor progression but loss of both
alleles having an inhibitory effect for tumor development implying
that one intact allele is needed for cell survival8.
A study led by one of the authors (DAH) identiﬁed germline lossof-function DICER1 mutations affecting the RNase IIIb domain in
affected families with pleuropulmonary blastoma (PPB)9, a rare
dysembryonic lung malignancy of childhood which was not the
only manifestation of this familial tumor predisposition syndrome;
germline and somatic DICER1 mutations were subsequently
identiﬁed in several other familial associated tumors in several
extrapulmonary sites (Table 1). Individuals with germline DICER1
mutations also had non-neoplastic conditions including macrocephaly, renal structural anomalies, retinal abnormalities, dental
perturbations, and the GLOW syndrome (global developmental
delay, lung cysts, overgrowth and Wilms tumor). These associations

1
Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 2Clinical Genetics Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, Rockville, MD, USA. 3International Pleuropulmonary Blastoma/DICER1 Registry, Children’s Minnesota, Minneapolis, MN, USA. 4Cancer and
Blood Disorders, Children’s Minnesota, Minneapolis, MN, USA. 5ResourcePath LLC, Sterling, VA, USA. 6Division of Pathology, Children’s National Medical Center, George
Washington University School of Medicine and Health Sciences, Washington, DC, USA. 7The Lauren V. Ackerman Laboratory of Surgical Pathology, Barnes-Jewish and St. Louis
Children’s Hospitals, Washington University Medical Center, St. Louis, MO, USA. ✉email: dehner@wustl.edu

Received: 12 May 2021 Revised: 9 August 2021 Accepted: 9 August 2021
Published online: 1 October 2021

I.A. González et al.

5
Table 1.

DICER1-associated neoplasms.

Pleuropulmonary blastoma (PPB) and PPB-like neoplasms
Pleuropulmonary blastoma, type I, IR, II, III
PPB-like Sertoli-Leydig cell tumor of lung
Pediatric cystic neoplasms and DICER1-sarcoma (anaplastic sarcoma of kidney)
Nasal chondromesenchymal hamartoma
Central nervous system sarcoma with rhabdomyosarcoma/PPB III-like features
Sertoli-Leydig cell tumor with and without heterologous features and type I PPB-like features
Peritoneal, ovarian and fallopian tube sarcoma with PPB-like features
DICER1-associated cystic hepatic neoplasm with type I PPB-like features
Cervical embryonal rhabdomyosarcoma
Teratoid and primitive neuroepithelial neoplasms
Cervical-thyroid teratoma
Malignant teratoid neoplasm of sacrococcygeal region
Ciliary body medulloepithelioma
Pituitary blastoma
Pineoblastoma

1234567890();,:

Embryonal tumor with multilayered rosettes
Thyroid
Multinodular hyperplasia (goiter)
Papillary thyroid carcinoma, invasive follicular variant
Follicular carcinoma, pediatric type
Poorly differentiated thyroid carcinoma, pediatric type
Intestine
Hamartomatous polyp with juvenile polyp-like features

encircle the DICER1 tumor predisposition syndrome (Online
Mendelian Inheritance in Man numbers 606241, 601200 and
138800), with the estimation that 90% of those affected by this
syndrome inherited a germline mutation from one of their parents,
with a pattern of autosomal dominant inheritance10.
Most of the tumors in this syndrome occur in affected
individuals with one inherited DICER1 mutation, mainly a loss-offunction mutation, and an acquired somatic missense DICER1
mutation within ﬁve hotspot codons in the RNase IIIb domain
(E1705, D1709, G1809, D1810 and E1813)11–14. These variants
result in a bias toward the production of 3p strands of miRNA with
loss of 5p strands of miRNA15. Although this is the most common
mutational pattern in DICER1-associated tumors, mosaicism for
missense variants in these same hotspot codons have also been
identiﬁed and are associated with a more severe phenotype;
mosaicism explains those cases of PPB and the other associated
tumors in a child without a DICER1 germline mutation10. The
estimated prevalence of pathogenic DICER1 variants in the general
population is ~1:10,600, and approximately 30,000 Americans
harbor pathogenic DICER1 mutations12,14; however, this prevalence is seemingly higher and is estimated at ~1:4600 in the adult
cancer population14.
Following the initial clinicopathologic report of the PPB as a
unique high grade, solid neoplasm of the lung presenting early in
the ﬁrst decade of life16, it was not until the International PPB
Registry (IPPBR) was established with the availability to study
additional cases that an apparent familial predisposition was
recognized as well as the occurrence of other extrapulmonary
tumors in these kindreds17. Later came the identiﬁcation of DICER1
variants in these affected kindreds9. After more than three
decades of this seminal observation16, numerous studies have
conﬁrmed the relationship between DICER1 variants in carriers and
the development of a range of neoplasms and non-neoplastic
conditions; these associations have served to clarify the molecular
Modern Pathology (2022) 35:4 – 22

genetic nature of previously known pathologic entities such as
cystic nephroma and Sertoli-Leydig cell tumor, but also to identify
and characterize entities which were included among other
apparently unrelated neoplastic processes or not recognized as
familial associated pathology18. Despite the disparate primary sites
of the DICER1-associated neoplasms, many of these tumors have
overlapping pathologic features to possibly reﬂect their origin in
sites of branching morphogenesis (lung, kidney, liver), a key
developmental role of DICER119,20. It had been noted earlier that
the conditional DICER1 knockout in the developing mouse lung
resulted in the formation of cysts with the failure in branching
morphogenesis; this observation served as the foundation for the
hypothesis that a DICER1 mutation may explain the morphogenesis of the initial cystic stage of PPB9,21.
PLEUROPULMONARY BLASTOMA (PPB)
Considerable progress has been made since the ﬁrst cases of PPB
were described almost 45 years ago when it was proposed that
this neoplasm was the nosologic equivalent to the other
dysembryonic neoplasms of childhood such as neuroblastoma
and Wilms tumor unlike the extant classic biphasic pulmonary
blastoma of Spencer which was a neoplasm predominantly of
adults22. The initial 11 cases of PPB were all large solid masses
arising in the lung and/or pleura and were composed in part of
embryonal-type rhabdomyosarcoma, nodules of chondrosarcoma,
primitive spindle and small round cells with blastemal features
and anaplasia; these tumors in retrospect were all examples of the
solid or type III PPB (Fig.1A–C)16. It was only later with additional
cases referred to the IPPBR that it appeared that the solid tumor
was the ultimate stage in the process of tumor progression from a
multicystic lung lesion, previously regarded as a congenital
pulmonary airway malformation (CPAM) type IV, to an intermediate mixed cystic and solid stage whose latter pathologic
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Fig. 1 Pleuropulmonary blastoma, type III. A Pleuropulmonary blastoma, type III occurring in a 3-year-old male as a large solid thoracic mass.
Piecemeal resection revealed a tan-white, myxoid and hemorrhagic neoplasm (one of the original 11 PPB cases). B Focus of embryonal type
rhabdomyosarcoma and nodule of malignant cartilage. C Another focus of primitive sarcoma with individual anaplastic cells including bizarre
mitotic ﬁgure.

features were those of the originally reported high grade solid
PPB23.
Two points in our evolving understanding of PPB set the stage
for the subsequent recognition of a tumor predisposition
syndrome: one was the report from the IPPBR of 45 patients with
PPB that revealed that 12 (27%) children had ﬁrst and second
degree relatives with other conditions including pulmonary
“cysts”, cystic nephroma, thyroid nodules and neoplasms and
rhabdomyosarcoma (RMS), among other tumors presenting in the
ﬁrst two decades of life17 and the second observation was the
existence of a morphologic spectrum of PPB that correlated with
age at diagnosis and clinical outcome23. This morphologic
transition ranged from a cystic lung lesion, typically recognized
in the ﬁrst year of life if not in utero, which was designated type I
(cystic) PPB, to a penultimate cystic and solid type II and the
ultimate solid type III PPB, the pathologic type identiﬁed in the
original 11 cases16. This temporal evolution from a cystic to a solid
tumor also allowed for the study of those factors involved in the
progression from a type I to type III PPB24. The latter observation
carried considerable importance given the excellent outcome of
type I PPB with a 5-year overall survival (OS) of over 90% to a
5-year OS of 71% and 53% in the case of type II and type III PPB,
respectively25.
Given the prognostic implication of the PPB type, an accurate
diagnosis and proper classiﬁcation, particularly in the case of type
I PPB with its potential erroneous interpretation as a CPAM, are of
utmost importance for appropriate clinical management. In more
detail, type I PPB is a multicystic well-demarcated lesion arising
from the peripheral or distal sac-like structures lined by a ﬂat to
low cuboidal epithelium and a variably collagenized stroma with a
ﬁne capillary network, and a discontinuous or continuous
subepithelial layer of small primitive round cells with or without
rhabdomyoblastic differentiation with a so-called cambium-like
layer appearance (Fig. 2A–D). In some cases scattered nodules of
cartilage with a fetal rather than sarcomatous appearance are also
present within the septa (Fig. 3)22–24. The small primitive
neoplastic cells may be conﬁned to the subepithelial zone or
expand and replace the background ﬁbrovascular stroma without
the formation of a grossly visible mass, a requisite feature of type II
PPB (Fig. 4). The cellularity of the septa can vary from hypo- to
hypercellular so that complete sampling of the cystic lesion is
necessary since the small primitive cells and/or rhabdomyoblasts
are focal with a limited distribution within the septa or are more
diffusely cellular and distributed to facilitate identiﬁcation so that
it is important to examine the entire specimen microscopically.
Regardless of the degree and extent of septal cellularity and
expansion, the absence of a grossly detectable mass differentiates
a type I from a type II PPB; microscopic features alone do not
differentiate a type I from a type II PPB in the absence of a mass.
The neoplastic cells may demonstrate apparent rhabdomyoblastic
differentiation or may require immunohistochemistry (IHC) for
desmin and myogenin. In the absence of a rhabdomyoblastic
phenotype, the small cells are diffusely positive for CD56 whose

presence still qualify as a type I PPB. A subset of otherwise
architecturally similar multicystic lesion lacking the primitive
round cells after a thorough examination represents an example
of type IR PPB to imply that the cystic PPB has either failed to
undergo tumor progression or possibly undergone regression24.
Type II and III PPBs in contrast are mass lesions, unlike type I
PPB, and have a solid high-grade pattern which is characterized by
a collage of primitive sarcomatous patterns including RMS with
embryonal features, nodules of fetal and/or sarcomatous cartilage,
islands and nests of compact blastema, primitive spindle cells and
scattered or groups of anaplastic cells (Fig. 5)19. The solid areas
and their composition of patterns vary from one tumor to another
in terms of one or more of these several patterns (Fig. 1B, C). The
pathologic diagnosis does not require the presence of each one of
these several patterns within any one particular tumor; some
tumors are dominated by one or another pattern so as to
potentially create some uncertainty as to whether a particular
neoplasm is a PPB, especially in a biopsy with its restricted sample
as to the various patterns. In some cases, molecular studies may
be necessary to determine the DICER1 status; however, the clinical
presentation should be correlated with the biopsy. The opportunity to appreciate the various patterns is often deferred since the
surgical resection of the lung is currently preceded by neoadjuvant chemotherapy, unlike the earlier cases with primary surgical
resection. Type II PPB is differentiated from type III by the presence
of residual microscopic cystic foci of type I PPB in addition to a
mass; however, a biopsy may only show the solid pattern and
does not permit differentiation of a type II from type III PPB since
the type I pattern is only appreciated in the post-treatment
resection. The identiﬁcation of residual cystic foci is important
since the OS is signiﬁcantly enhanced in the case of type II PPB
compared to type III25.
Given the rarity of PPB and the range of morphologic features, it
is not altogether surprising that approximately 20% of the cases
sent to the IPPBR are not PPBs, but true congenital lung cysts,
cystic pleuropulmonary synovial sarcoma and other solid neoplasms such as Ewing sarcoma and even sarcomatoid carcinoma25. In the presence of an exclusive spindle cell sarcomatous
pattern in a lung neoplasm from an older child or adolescent with
the question of a PPB, synovial sarcoma should be considered26.
This latter experience highlights the desirability of a central review
of an extraordinarily rare tumor such as the PPB.
Harris et al.21, provided the foundation that DICER1 may explain
the cystic stage since its inactivation in the mouse model resulted
in lung cysts resembling type I PPB. A genetic study of 11 affected
families with PPBs and other tumors revealed a heterozygous
DICER1 germline mutation with loss-of-function mutation affecting
the RNase IIIb9. It is currently estimated that at least 70% of
patients with a PPB have a germline DICER1 variant25. Mosaicism
for RNase IIIb domain missense mutations is associated with a
more aggressive phenotype10,27. An explanation for this apparent
phenotypic difference from the germline cases remains unclear
to date.

Modern Pathology (2022) 35:4 – 22
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Fig. 2 Pleuropulmonary blastoma, type I presenting as a cystic lesion in the lung of a 1-year-old female. A Septal markings and cysts are
appreciated in this unbisected specimen whose multicystic structure is lost with bisection as the delicate septa collapse. B The peripheral
multicystic lesion is composed of uniform septal structures abutting the pleural surface, a characteristic feature. C Uniformly expanded septa
by primitive-appearing small, rounded and spindled-shaped cells, many showing desmin and myogenin positivity (not shown). D Cambium
layer-like concentration of primitive small cells with adjacent ﬁbrous stroma.

Fig. 3 Pleuropulmonary blastoma, type I showing septal widening. Pleuropulmonary blastoma, type I showing a focus of septal
widening by primitive small cells as a feature of presumed
progression before the formation of a grossly visible mass, as a
requisite for the diagnosis of type II PPB.

Fig. 4 Pleuropulmonary blastoma, type I showing a nodule of
cartilage within a septum. This ﬁnding is seen in 15% of type I PPBs,
as one or several foci.
Modern Pathology (2022) 35:4 – 22

It was appreciated that biallelic DICER1 mutations were
probably insufﬁcient for the progression of type I PPB to types II
or III and that an additional mutation(s) was probably necessary
and these include TP53 and NRAS mutations10,28–31. This observation may explain in part that a subset of type I PPBs lacks the
intrinsic potential to progress beyond the purely cystic stage
without rhabdomyoblasts and/or small primitive cells as in type IR
PPB (Fig. 6)21. More recently, it has been demonstrated that TP53
expression by IHC correlates with the prognosis in PPB
independent of the three PPB types; this observation validated
the hypothesis that other mutations are necessary for tumor
progression from type I to type III PPB32. Furthermore, it was noted
in the latter study that the presence of TP53 expression in the
epithelial cells lining the cystic structures in most type II PPBs but
in less than 50% of type I PPB and in less than 20% of type IR
raised the question of the role that the epithelium plays in tumor
progression independent of mutations in the mesenchymalstromal cells.
Murray et al, on the basis of the increased 3p miRNA
hypothesized that the serum levels of miRNA could be used as
a screening test for PPB33. Increased serum miRNA levels at the
time of PPB diagnosis was detected in a patient with a germline
DICER1 mutation which decreased after treatment with chemotherapy. It is still unclear at present what are the implications or
the utility of using serum levels of miRNA as either a screening
tool, biomarker or as a possible option for follow-up. A prospective
population-based study is needed to further answer these
questions34.
On the basis of our current understanding of DICER1 and PPB,
the IPPBR recommends that a chest x-ray should be obtained for
all at risk children at the time of birth to screen for lung cyst(s).
Children with a proven germline mutation should have a chest
computed tomography (CT) by 9-months of age for a type I PPB so
that resection can be performed before possible progression to
PPB type II/III31. If the chest CT is normal, a follow-up low dose
scan is recommended at 2.5-years of age which is prior to the
peak incidence of type II and III PPB35. It is clear that not all type I
PPBs progress to the clinically more aggressive type II/III PPB since
type IR PPB is regarded as the failure of tumor progression beyond
type I PPB. However, it is necessary to resect the multicystic lesion
to determine whether it is type I or type IR PPB (Fig. 6).
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Fig. 5 Pleuropulmonary blastoma, type II. A Focus of PPB type I in a mass lesion in this 2-year-old male whose tumor was predominantly
solid. B, C A cambium layer-like growth pattern in this transitional area from type I to the solid pattern. D Solid focus showing a mixture of
small primitive round and spindle cells.

pregnancy-related thyroid enlargement as an established manifestation of DICER1 tumor predisposition syndrome37.

Fig. 6 Pleuropulmonary blastoma, type IR. Pleuropulmonary
blastoma, type IR showing the characteristic multicystic architecture
of type I, but in the absence of a primitive small cell or
rhabdomyoblastic population only ascertained after a complete
microscopic examination of the resected cyst.

THE FEMALE REPRODUCTIVE SYSTEM
Germline pathogenic mutations in DICER1 are associated with
different tumor types affecting the female reproductive system;
the two most common are Sertoli-Leydig cell tumors (SLCT) and
cervical embryonal rhabdomyosarcoma (cERMS). Merideth
et al.36, reported on their ﬁndings in women DICER1 carriers
from the non-neoplastic gynecologic perspective. Among DICER1
carriers the mean age of menarche was 12.7 years (range: 10–16
years) with no reports of precocious puberty. Among those
women with a history of prior chemotherapy and/or radiation
due to a prior PPB, the age of menarche was similar to the
general population36. All 64 DICER1 carriers included in the latter
study had a normal female phenotype and normal Tanner
staging for age. Of the pregnancies identiﬁed in this population,
21% resulted in spontaneous miscarriage, 3.6% in ﬁrst trimester
termination, one (0.9%) ectopic pregnancy, and 75% completed
pregnancies with only 5% resulting in preterm delivery. Notably,
10 of the 32 (31%) patients that conceived experienced
pregnancy-related goiter which resulted in a thyroidectomy
within one-year of pregnancy36. This study highlights the
importance of the awareness of the spectrum of gynecologic
and obstetric ﬁndings in DICER1 carriers, especially the

Ovarian sex cord-stromal tumors (OSCST)
OSCSTs are a heterogenous groups of tumors representing
approximately 5% of all primary ovarian neoplasms which can
present in adolescence and young adulthood, if not earlier as in
the case of the juvenile granulosa cell tumor. These tumors are
classiﬁed according to pure stromal types (Leydig cell tumor,
steroid cell tumor), pure sex cord types (adult and juvenile
granulosa cell tumors, Sertoli cell tumor) and mixed sex cordstromal types (Sertoli-Leydig cell tumor, gynandroblastoma)38. In
addition to an adnexal mass, they may have functional signs due
to hormonal production such as hirsutism and virilization,
menstrual changes or precocious pseudo-puberty39,40. Importantly, OSCSTs are also associated with other underlying predisposition syndromes such as Peutz-Jeghers and Ollier-Maffucci
syndromes41–43.
The International Ovarian and Testicular Stromal Tumor Registry
(IOTSTR) reported that SLCT was one of the more common
DICER1-associated neoplasms and the most common ovarian
tumor overall in the DICER1 syndrome44–53. Germ cell tumors have
also been reported in family members of those with a PPB,
including a dysgerminoma and three seminomas49. Slade et al
identiﬁed only one case of germ cell tumor, a seminoma, with a
biallelic DICER1 mutation among 172 germ cell tumors5. Other
ovarian tumors associated with DICER1 mutations include juvenile
granulosa cell tumor, yolk sac tumor, teratomas and mixed germ
cell tumors; these tumors compared to SLCT may represent
coincidences since it is uncertain whether DICER1 carriers are at an
increased risk for germ cell tumors46,50,51.
Sertoli-Leydig cell tumor (SLCT). SLCT represents less than 1% of
all primary ovarian tumors and is seen in a broad age range from
infancy into the later adult years, but approximately 75% of cases
present in women less than 30-years of age54. It was appreciated
over 50 years ago that there was of an apparent association
between the SLCT, multinodular goiter and cERMS54–58. In a cohort
of 64 cases of intermediate and poorly differentiated SLCT, three
patients had a history of a thyroid nodule or goiter55. Young and
Scully also noted that two patients had a cERMS and four others
had a thyroid “abnormality” in their study of ovarian SLCTs, to
suggest that this association was more common in those women
with an intermediate and poorly-differentiated SLCTs54. Once the
linkage of DICER1 and familial PPB cases was reported in 20099,
subsequent studies documented the linkage of DICER1 with SLCT
as well as with FOXL245. Pathologically, most SLCTs in the DICER1
Modern Pathology (2022) 35:4 – 22
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Fig. 7 Sertoli-Leydig cell tumor, moderately differentiated in an adolescent presenting with an abdominal mass. A Solid foci of this solid
and cystic mass showing groups of Sertoli cells and surrounding Leydig cells. B Cystic focus with a delicate septum with a cambium layer-like
localization of Sertoli cells with its resemblance to PPB type I.

Fig. 8 Sertoli-Leydig cell tumor, moderately differentiated in a 15-year-old female. A A cystic focus showing a group of Sertoli cells
beneath a low cuboidal epithelial surface. B Nests of Sertoli cells surrounded by malignant-appearing, primitive-appearing spindle and round
cells in another cystic area of the tumor. C MyoD immunostaining showing intense nuclear positivity to corroborate heterologous
rhabdomyosarcoma.

setting have been moderately (intermediate) or poorly differentiated tumors (Fig. 7A, B); some of these neoplasms have had
heterologous elements including nodules of cartilage and
rhabdomyosarcoma; the latter combination of patterns has been
observed in SLCT in addition to PPB as already noted and in other
DICER1-associated tumors (Fig. 8A–C)23,59. The SLCT may have a
localized multicystic pattern with more than a passing resemblance to type I PPB.
Heravi-Moussavi et al. conducted the ﬁrst comprehensive
analysis of DICER1 in OSCSTs and identiﬁed a DICER1 mutation
in 60% of SLCTs, all of which were restricted to the RNase IIIb
domain; in addition to a second germline mutation in a subset of
cases; they also found DICER1 mutations in 1 of 14 nonseminomatous testicular germ cell tumors, 2 of 5 ERMS, and in 1 of 266
epithelial ovarian and endometrial carcinomas50. Following this
report, other studies have reported a similar incidence of DICER1
mutation in SLCT, ranging from 32% to 98% of cases44–48,51,53. This
broad range is partially explained by the enriched population bias
for DICER1 carriers in some of the studies. Additionally,
intermediate or poorly differentiated SLCTs are almost universally
associated with a DICER1 mutation with a prevalence of 97% to
100% compared to well-differentiated cases of which only 12% in
one study were associated with a DICER1 mutation47,48,53. Given
this strong association of DICER1 mutation in SLCT, it is probably
advisable for appropriate tissue testing especially in the younger
age patients with moderately to poorly differentiated SLCTs with
retiform or heterologous features. DICER1-associated SLCTs present at a younger age compared to the sporadic SLCT44–47,51.
About 50% of DICER1-associated SLCTs are stage Ia and are free of
disease after a median follow-up of 19 months in contrast to the

Modern Pathology (2022) 35:4 – 22

sporadic tumors in which approximately 15% of patients had a
recurrence47.
One particularly unusual example of a SLCT was one that
presented in the lung as a cystic and solid mass in a 1-year-old
male which was thought clinically to represent a PPB and was
referred to the IPPBR (unpublished case). The tumor had
pathogenic variant of DICER1. This case serves as an extraordinary
example that DICER1-associated neoplasms are not restricted to
the usual sites of presentation as in the case of PPB-like sarcomas
arising in the kidney or peritoneum.
Gynandroblastoma. Gynandroblastoma is a sex-cord tumor with
Sertoli-Leydig cell and an adult or juvenile granulosa cell
pattern39,49, which predominantly occurs in the ovary with only
the rare example in the testis60. The IOTSTR/IPPBR reported one
case of gynandroblastoma in a patient with a germline DICER1
mutation among 325 OSCSTs from 296 families with PPB49. Five
additional cases in patients from 14- to 32-years of age (median
age 16-years) have been reported subsequently by the IOTSTR47.
In these cases, the SLCT component had intermediate differentiation and most cases were stage Ia. Four cases of the ﬁve were
sequenced and all four had a DICER1 RNase IIIb hotspot mutation;
three of the four patients had a germline DICER1 loss-of-function
mutation47.
Another study evaluated a large cohort of gynandroblastomas
consisting of 16 cases in patients from 14- to 80-years of age
(median age 24.5-years); the granulosa cell tumor component in
10 cases had juvenile features with solid nodules of polygonal
cells with or without luteinized features and follicular-like
structures with granular basophilic secretions (62.5%)61. Only
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Fig. 9 Embryonal rhabdomyosarcoma of the cervix. A A polypoid “vaginal” tumor presented in a 9-year-old female showing scattered
endocervical glands with variably prominent subepithelial concentration of small cells and nodules of cartilage. PPB-type IR was also detected
in the lung and a pathogenic heterozygous germline DICER1 mutation was detected. B Endocervical gland encircled by embryonal
rhabdomyosarcoma in an 11-year-old female with a cervical-vaginal mass. She subsequently developed a Sertoli-Leydig cell tumor at age 13
years and had a pathogenic heterozygous germline DICER1 mutation.

three cases had a DICER1 hotspot mutation but importantly all of
these cases had features of a moderate to poorly differentiated
SLCT component with a juvenile granulosa cell component61.
None of the cases had a FOXL2 mutation. Of 26 gynandroblastomas tested for DICER1, ten (38%) had hotspot DICER1 mutations
within the RNase IIIb domain47–49,61. When a gynandroblastoma is
encountered especially in the presence of an intermediate or
poorly differentiated SLCT component, appropriate tissue testing
and genetic counseling are indicated since DICER1 carriers have an
increased risk for the development of SLCT and gynandroblastoma. A pelvic ultrasound every 6 to 12 months is recommended
until at least 40-years of age35.
Embryonal rhabdomyosarcoma of the cervix (cERMS)
One of the early reports of cERMS consisted of 13 cases in patients
between 12- and 26-years of age who presented with vaginal
bleeding62. In contrast to vaginal RMS with a median age at
diagnosis of 2 years, cERMS is seen in older children, adolescents
and young adults with a median age of 13–14 years63. However, a
vaginal biopsy of an ERMS does not permit a distinction between
a vaginal and cervical origin, but as noted the age at presentation
as well as additional clinical studies may be helpful in the
individual case. Uterine RMS presenting in the cervix of an adult
occurs in younger age women than in those arising in the
corpus64. The cERMS typically has the features of the favorable
botryoid ERMS with a cambium layer and in almost 50% of
the cases foci of cartilage are identiﬁed, a seemingly unique
feature of ERMS within the DICER1 setting unlike the absence of
cartilage in the sporadic ERMS (Fig. 9A, B); this same combination
of ERMS and cartilage is present in PPB as well as other DICER1associated neoplasms. A noteworthy ﬁnding in the report of 13
cases was a prior history of SLCT in two patients; the authors
stated that “the combination of a rare cervical tumor and a rare
ovarian tumor in these two patients suggests more than a chance
association”62. Subsequent reports have documented this association, one in a 27-year-old woman with a SLCT and a prior history of
a cERMS at 14-years of age65, and another in a 13-year-old
presenting with a synchronous SLCT and cERMS66.
The association of cERMS and SLCT was later reported in a
cohort of 14 cases; these patients presented from 9-months to 32years of age67. In addition to the botryoid pattern of ERMS, the
hypocellular myxoid stroma in 6 cases (43%) contained one or
more nodules of cartilage (Fig. 9A, B). One patient had a history of
type IR PPB in early childhood and was found to have a germline
DICER1 mutation. Another patient had a history of type II PPB, with
an unknown DICER1 status and a third patient had a history of

multinodular goiter and a SLCT67. Prior to the latter report, Foulkes
et al identiﬁed four patients with cERMS, all of whom had a
germline DICER1 mutation68. Another case was subsequently
reported in a 13-year-old female with cERMS and type IR PPB
which was found to have a deleterious germline mutation in exon
12 as well as a somatic mutation69. Two additional cases of cERMS
with a germline DICER1 loss-of-function mutation have been
reported70. These studies present the case that cERMS is a DICERassociated tumor. Molecular studies should be performed in the
problematic case of an ERMS presenting as a vaginal mass.
Given the association of DICER1 mutations with cERMS, de Kock
and colleagues71 sought to evaluate the practical utility of DICER1
testing as an aid in the challenging differential diagnosis of uterine
adenosarcoma; these authors assessed 19 cERMS and 27 uterine
adenosarcomas with a consensus diagnosis, and found that 18
cases (95%) of cERMS had a DICER1 mutation compared to 7 cases
(26%) of uterine adenosarcoma. Germline DICER1 mutations were
only identiﬁed in those with cERMS (6 of 12 cases tested) and in
none of the adenosarcoma cases tested. Based on these results an
absence rather than the presence of DICER1 mutation could aid
in this differential diagnosis, but a careful morphologic assessment
of these tumors generally settles the diagnostic dilemma. A cERMS
has an exclusive pattern of RMS whereas adenosarcoma is usually
a low-grade spindle cell sarcoma.
ERMSs arising elsewhere in the genitourinary tract have been
associated with DICER1 syndrome; three cases with germline lossof-function mutations have been described in the urinary
bladder70, one case in the fallopian tube with a germline DICER1
mutation, two cases in the ovary with somatic DICER1 mutations72,
and another case in the ovary with a germline DICER1 mutation in
exon 8 and a somatic mutation73. The ERMS in the fallopian tube
and ovaries showed a cambium-like layer and nodules of mature
cartilage; these histologic features overlap with PPB and cERMS.
Unfortunately the ERMS of the urinary bladder did not have an
available histologic description70. As with other suspected
examples of DICER1-associated neoplasms, especially nonvaginal ERMS in the müllerian tract, appropriate molecular testing
on the neoplasm should be pursued in addition to a discussion
with the clinician35,74.
PEDIATRIC PARATESTICULAR SARCOMAS
Paratesticular neoplasms are those tumors arising from the
testicular collecting system, the tunica and the spermatic cord;
these tumors are uncommon and approximately 30% are
malignant of which over 90% represent sarcomas with
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Fig. 10 Cystic nephroma, pediatric type. A Circumscribed multicystic renal lesion in this CT image from a 2-year-old male who presented
with an abdominal mass. A similar-appearing lesion on CT was present in the lung (PPB type I not shown). B Several delicate septal structures
display architectural similarities to PPB type IR. C Multiple cysts in a ﬁbrous stroma and one larger cyst with a hypercellular subepithelial
mantle of spindle cells with a resemblance to PPB type I. Overtly sarcomatous elements were not present.

liposarcomas as the most common type75,76. Paratesticular
sarcomas in children are principally ERMSs with or without a
spindle cell pattern or spindle cell RMS in 75% or more of cases
presenting in infancy or adolescence77. A DICER1 mutation was
identiﬁed in one low-grade “myxoid” sarcoma among 15
paratesticular sarcomas in children78; this tumor was composed
of small cells embedded in a myxoid background with no increase
in mitosis or anaplasia. There was an absence of rhabdomyoblastic
or chondroid elements unlike several other examples of DICER1associated extrapulmonary sarcomas. The presentation of a
DICER1-associated neoplasm in the male reproductive tract
contrasts at the moment with the apparent more common
occurrence in females18,79.
It is recognized that a primary intraabdominal neoplasm may
metastasize or directly extend from an abdominal or retroperitoneal location. Though we have not encountered a case as
yet, a primary PPB-like peritoneal sarcoma presenting as a scrotal
mass is a potential clinical scenario.
THE URINARY SYSTEM
Similar to the lung, where DICER1 is essential for the branching
morphogenesis of the epithelium19,80,81, the loss of DICER1
expression in the developing kidney results in apoptosis in the
progenitor nephron epithelium and premature termination of
nephrogenesis and the development of renal cysts due to the
apoptosis and loss of cell proliferation20,80,81. In addition, loss of
DICER1 function from the collecting duct epithelium is associated
with hydronephrosis and collecting duct cysts82. In light of these
ﬁndings in animal models, DICER1 is considered essential for
the survival of the nephron epithelium and differentiation of the
ureteric bud epithelium. It is not entirely surprising that some
patients with a PPB also had a cystic nephroma (CN) or a family
history of CN83. The earlier paradigm was that CN in children was a
representative of the Wilms tumor spectrum which was also
thought to include the so-called adult CN/mixed epithelial and
stromal tumor84–86. However, the latter neoplasm is regarded as a
separate entity from pediatric CN and only rarely has a DICER
mutation87,88.
Given the importance of DICER1 in the development of the
urinary system, a comprehensive evaluation of 89 individual
DICER1 carriers was compared to 61 family controls89. The
presence of “renal cysts” was similar in both groups, 17% and
22% of known DICER1 carriers and family controls, respectively
with no differences in renal function between the two groups.
Only the DICER1 carriers had ﬁndings of nephrolithiasis or
nephrocalcinosis which was present in 8 individuals (9%)89. To
date, this is the most comprehensive study characterizing the
spectrum of non-neoplastic renal abnormalities in DICER1 carriers,
and further studies with a larger population-based analysis are
needed to further understand the full impact of germline DICER1
mutations upon renal development and function.
Modern Pathology (2022) 35:4 – 22

Cystic nephroma (CN) and anaplastic (DICER1) sarcoma of
kidney (ASK)
Pediatric CN (pCN) is a multiloculated cystic neoplasm presenting
at or before 4-years of age as an unilateral, well-demarcated renal
mass (Fig. 10A–C)85,88. Histologically, the cystic structures are lined
by a simple epithelium with ﬂat, cuboidal or hobnail features
and the septa are composed of a bland ﬁbrous stroma with
scattered entrapped benign tubular structures, whose architectural features are similar to type I or IR PPB (Fig. 10B, C). The
stroma is devoid of any immature nephroblastic elements which is
the essential distinguishing histologic feature from the cystic
partially differentiated nephroblastoma (CPDN)84,88.
In a report from the IPPBR, it was noted that there was a familial
association between PPB and pCN in approximately 12% of cases;
the pCN presented synchronously with the PPB in 10% of cases90.
With the recognition of germline DICER1 mutation in PPB9, the
status of DICER1 in 20 pCNs was evaluated and 70% of cases had
an biallelic loss-of-function DICER1 mutation, all of which were
considered as a deleterious truncating mutations91. None of the
CPDNs had a DICER1 mutation to dichotomize these two tumors
from each other. Unfortunately, germline testing was not
performed in these cases but based upon our prior ﬁndings,
80% of DICER1 loss-of-function mutations are germline in PPB29. In
an earlier study by Bahubeshi et al., two families with familial CN
were found to have a DICER1 mutation in exon 23 in one family
and in exon 25 in the other92. To date, the presence or absence of
a DICER1 mutation distinguishes a pCN from CPDN87.
Given the potential of type I PPB to progress to a high grade
multipatterned primitive sarcoma, the question was whether a
similar phenomenon of tumor progression occurred in the case of
pCN. Tumor progression in the pCN was extremely uncommon as
documented by only four cases in the IPPBR experience, but there
was considerable pathologic overlap between the sarcoma arising
in pCN and the solid component of type II/III PPB91. These renal
sarcomas have been designated previously as anaplastic sarcomas
of the kidney (ASK) which like type II/III PPB may or may not have
obvious anaplasia in every case (Fig. 11A–C)93. The cysts of the
ASK are indistinguishable from pCN. Faria and Zerbini documented a predominantly cystic mass of the kidney with solid areas
composed of rhabdomyoblastic and cartilaginous differentiation
in a 26-month-old girl94; these authors commented upon the
apparent sarcomatous transformation of a pCN and the pathologic
similarities to PPB. A similar case in a 19-year-old male was
composed of primitive mesenchyme in a myxoid background with
accompanying cystic spaces95. Another case in a 4-year-old boy
was a multilobulated renal mass composed of primitive small cells
with rhabdomyoblastic differentiation with features similar to type
II PPB96. In a review of 20 ASKs, the microscopic collage consisted
of spindle cells merging with primitive mesenchymal cells,
anaplasia and chondroid nodules in 16 of 20 cases and a cystic
component in 7 cases; these tumors, as noted by the authors,
were similar to types II/III PPB93. Despite the appreciation of the
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Fig. 11 Anaplastic sarcoma of kidney (DICER1 renal sarcoma) in the right kidney of a 4-year-old male. A The solid and cystic neoplasm
showing a focus of residual pCN and adjacent cysts with surrounding hypercellular mantles of primitive small cells with rhabdomyoblastic
differentiation (not shown) (inset, focus of hyperchromatic cells beneath a cyst). B A focus of primitive small, round and spindle-shaped cells
projecting into a cyst with a subepithelial mantle of similar-appearing cells. C Malignant-appearing spindle cells surrounding a focus of
neoplastic cartilage. D Focus of undifferentiated round cells with adjacent neoplastic cartilage. As in the case of PPB types II and III, anaplasia is
not present in every ASK despite the implication of its appellation.

similarities of pCN and ASK to PPB type I and types II/III, DICER1
testing was not available in these cases93–97. A later study from the
IPPBR of four ASKs on which DICER1 testing was performed on
three, two had a DICER1 mutation, one with an exon 14 nonsense
mutation and a missense hotspot mutation, and the other had a
somatic missense mutation91. More recently, nine cases of ASK
were evaluated for DICER1 and TP53 mutations98; 8 cases had a
somatic RNase IIIb DICER1 mutation and overexpression of TP53
by IHC was seen in 6 of 9 cases, but only three cases had a TP53
mutation98.
Given the association of pCN and DICER1 carriers, and the rare
progression to ASK-DICER1 renal sarcoma, an abdominal ultrasound is recommended during infancy at the time a chest CT is
done for PPB surveillance and every 6 to 12 months until at least
8-years of age. After this age, an annual ultrasound could be
considered until 12-years of age32.
Wilms tumor (WT)
WT is the most common primary renal neoplasm of childhood
with 15% of cases associated with a familial predisposition
syndrome including the linkage with mutations/deletions in WT1
(11p13) and others that pre-dispose to WT99–101. Among 375
children with PPB and their families, only four cases (1%) of WT
were identiﬁed; only one case developed in a child with a history
of PPB whereas the other cases occurred in family members of
those who had a PPB91. Prior to the documentation of these latter
four cases, prior studies have analyzed the DICER1 status in
WT5,92,102. In one study of 50 sporadic WTs, none had a DICER1
mutation92. Another study evaluated 243 WTs and detected only
1 case (0.4%) with a DICER1 mutation; this same patient also
developed bilateral OSLCT5. Wu et al examined 191 sporadic WTs
and found ﬁve different somatic DICER1 mutations in four
patients; these same authors reported three patients with
hereditary WT who were found to have germline DICER1
mutations and an additional somatic mutation102. Although very
uncommon WT can be associated with DICER1 germline
mutations whose pathogenetic role remains undeﬁned at
present.

THE GASTROINTESTINAL SYSTEM
The gastrointestinal system is the site of involvement by several
syndromes and DICER1 tumor predisposition syndrome is no
exception103,104.
DICER1-associated cystic hepatic neoplasm
The association of DICER1 mutation with hepatic manifestations
was reported in two cases of “mesenchymal hamartoma” of the
liver (MHL) in 26-month-old and 75-month-old boys; both children
had heterozygous pathogenic DICER1 variants and an accompanying somatic hot-spot RNase IIIb DICER1 mutation, in one case,
and a heterozygous in-frame germline deletion in the other, but a
somatic mutation was not seen105.
Dispute over the nature of these cystic tumors arose over their
interpretation as MHLs since the latter infantile neoplasm has a
well-documented activation of chromosome 19q microRNA
cluster106,107. MHL is a cystic lesion which is characterized by a
loosely cellular myxoid stroma with scattered, small dysplastic or
malformed bile ducts resembling those of a bile duct plate
abnormality and isolated islands of hepatocytes. Vargas and PerezAtayde108 opined that the two cases of DICER1-associated MHL
were not examples of classic MHL, but rather another type of
cystic lesion of the liver. It could have been argued that both
lesions of the liver had architectural similarities to type IR PPB or
pCN. We have had an opportunity to study a case of a multicystic
hepatic lesion from a 1-year-old infant who had a DICER germline
mutation. The epithelial-lined cysts were surrounded by a
cambium layer of rhabdomyoblasts and others with a concentric
ﬁbrous stroma; this multicystic lesion has the architectural and
histologic features of type I PPB to conform with the familiar
morphologic paradigm (Fig. 12). It is important to distinguish this
novel cystic hepatic neoplasm with a DICER1 mutation from classic
MHL with its pathogenetic relationship to undifferentiated
embryonal sarcoma liver107,109. More recently, a very similar cystic
neoplasm of the liver to one described here has been reported
whose pathologic features are similar to type I PPB with spindle
cell sarcomatous progression in a young patient with a germline
DICER1 variant110.
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Fig. 12 DICER1 cystic hepatic neoplasm presenting as a cystic
lesion of the liver in a 1-year-old male. A 10.7 cm mass with a
multicystic cut surface showing one of multiple cysts lined by biliary
type epithelium with a subepithelial zone of primitive small cells
extending into the surrounding stroma. These cells demonstrated
desmin immunopositivity. A pathogenic heterozygous germline
mutation in DICER1 was detected.

they are more aligned with hamartomatous types. Lallier M et al
reported a case of bilateral PPBs and bowel obstruction due to
multiple small intestinal polyps in a 5-week-old girl which was also
documented in another study90,114. This patient also developed a
cystic lesion in the kidney without pathologic conﬁrmation, but
likely represented a pCN in addition to another lesion in the iris
which was thought to be metastatic PPB, but was more likely a
ciliary body medulloepithelioma. At the time of publication114, the
association with DICER1 and PPB was still unknown but in
retrospect, this child was manifesting the various DICER1associated tumor types. The intestinal polyps in this child were
interpreted at the time as “juvenile polyps” without a histologic
description or illustration114. Other better documented cases of
hamartomatous polyps in DICER1 carriers include a 19-year-old
female with a type I PPB, bilateral pCNs and an ileal intussusception due to a 3.2 cm “juvenile polyp”90. Other examples of
intestinal polyps include a 2-year-old girl with an “hamartomatous
esophageal polyp”68 and a 9-month-old girl with a type I PPB and
a jejunal hamartomatous polyp115. Five children with PPB, pCN
and small intestinal intussusception due to polyps and two
children with PPB and small intestinal polyp have also been
reported116. A thorough pathologic characterization of these
various polyps has remained incomplete.
A previously unpublished case of a hamartomatous polyp in a
patient with a history of PPB is presented here to provide a
somewhat more detailed description of the pathologic features.
The polyp had bands of smooth muscle haphazardly arranged
through the lamina propria and extending to the surface without
the arborizing and lobulated architecture of a PJP. There were no
dilated crypts or inﬂammation of the lamina propria which are
often present in the typical juvenile polyp (Fig. 13). In addition, the
polyp had a prominent vascular pattern with dilated vessels
highlighted with CD31 and CD34 in the intestinal villi, and a
complex anastomosing dilated lymphatic spaces which extended
into the stalk of the polyp, highlighted by a D2-40 immunostain.
THE PERITONEUM AND RETROPERITONEUM
Two recent additions to the spectrum of DICER1-associated tumors
include the peritoneal sarcoma with the designation of PPB-like
peritoneal sarcoma117, and a presacral malignant teratoid
neoplasm118.

Fig. 13 Hamartomatous polyp with juvenile polyp-like features.
Small intestinal polyp in a child with PPB showing an ulcerated
surface with elongated crypts and a lamina propria with bands of
smooth muscle.

DICER1-associated hamartomatous polyps
Intestinal polyps are broadly classiﬁed into hamartomas and
neoplastic/pre-neoplastic polyps. Hamartomatous polyps are
benign proliferations of epithelial and mesenchymal elements
presenting mainly in children and young adults. These polyps
occur as either a sporadic lesion or in the setting of a polyposis
syndrome with an increased risk for malignancy. The three types of
hamartomatous polyps include juvenile polyps/juvenile polyposis
syndrome, Peutz-Jeghers polyps of PJ syndrome and hamartomatous polyps in the PTEN hamartoma tumor syndrome111–113.
Though the reports of intestinal polyps in the DICER1 setting are
not detailed in terms of their pathology features, it appears that
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Pleuropulmonary blastoma-like peritoneal sarcoma
Primitive sarcoma resembling PPB presenting in the peritoneal
cavity has been reported in 7 children from 3 to 14 years with the
fallopian tube (4 cases), pelvic sidewall (2 cases) and serosa of the
colon as the apparent primary site117. None of these children had
a past or contemporaneous history of PPB or other DICER1–
associated neoplasms. The tumors all shared the morphologic
spectrum of PPB including cystic spaces with underlying primitive
small cells with or without rhabdomyoblastic differentiation
(sarcoma botryoides-like pattern and nodules of cartilage similar
to type I PPB; multilocular peritoneal cysts without underlying
primitive mesenchymal cells resembling type IR PPB; and the
remaining cases with cystic and solid features or a purely solid
multipatterned primitive sarcoma of type II/III PPB (Fig. 14A, B).
These similarities to PPB suggested a temporal progression from a
simple multiloculated cyst to a solid multipatterned primitive
sarcoma; however, this remains to be conﬁrmed with the inclusion
of additional cases. McCluggage and associates have reported
three cases similar to our experience in addition to an ovarian
ERMS119. Not only were there the overlapping morphologic
features of PPB as in our series117, but biallelic loss of function
RNase IIIb DICER1 mutations were detected in six cases with
available DNA and germline DICER1 mutations were also present
in four of the ﬁve patients119.
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Fig. 14 PPB-like peritoneal sarcoma arising in the pelvis of an adolescent female. A Cystic focus of the tumor demonstrating a hypercellular
zone of primitive round cells with patchy myogenin positivity (not shown). B Solid areas of the tumor showing undifferentiated sarcoma with
round and spindle cell features and an enlarged, anaplastic tumor cell.

Prior to the characterization of PPB-like peritoneal sarcoma as
a distinct entity, Warren et al reported two cases in 5-year old
and 16-year old girls who presented with a right adnexal mass
and a pelvic mass with omental and peritoneal metastases,
respectively; these two cases as pointed out by the authors had
pathologic features of types II/III PPB; both cases had a somatic
DICER1 mutation in addition to a germline mutation in one case
which was the only one tested79. The authors also reviewed a
total of 83 DICER1-associated sarcomas from the literature and
concluded that there was a common morphologic motif
with PPB of small primitive round cells, poorly differentiated
spindle cells, primitive rhabdomyoblasts with a botryoid or
nested pattern, chondroid nodules and anaplasia79. We would
concur that any combination of these patterns or a predominance of one of these patterns should raise the possibility of a
DICER1-associated neoplasm to initiate appropriate molecular
testing, regardless of the site of presentation in a child or
adolescent.
DICER1-associated presacral malignant teratoid neoplasm
The most common sacrococcygeal neoplasm in the pediatric-aged
population is the teratoma, representing over 90% of cases in this
site120. Approximately 40–50% of all germ cell tumors in children
present in the sacrococcygeal region121. Presacral teratomas are
divisible into mature and immature types with malignancy usually
represented by yolk sac tumor as multiple microscopic foci in
those tumors presenting in infancy. More importantly to the best
of our knowledge, the presence of ERMS in an infantile presacral
teratoma should alert to the possibility that the tumor may
represent a DICER1-associated neoplasm120,121. On the other hand,
germ cell tumors of the testis in particular may give rise to a soft
tissue sarcoma, including ERMS in less than 10% of cases in young
adults122.
Two originally interpreted presacral immature teratomas
presenting in a 1-week old boy and in a 4-month-old girl were
found to have DICER1 mutations in retrospect, speciﬁcally two
nonsynonymous variants in one case, and a pathogenic
germline DICER1 mutation and a somatic hot-spot DICER1
mutation in the other118. Both tumors had a distinct morphology composed of primitive neuroepithelial proﬁles and
mesenchymal cells, spindle cells, and rhabdomyoblasts which
were accompanied by nodules of primitive cartilage whose
features should be familiar at this juncture with their similarities
to other DICER1-associated tumors. It is important to be aware
of this teratoid neoplasm because of its overlapping features
with the immature sacrococcygeal teratoma. However, immature cartilage in association with spindle cells and rhabdomyoblasts should in the absence of other teratomatous elements
and/or yolk sac tumor raise the possibility of DICER1-associated
presacral malignant teratoid neoplasm.

HEAD AND NECK
Thyroid gland
Multinodular goiter (MNG) is the clinical designation for an
enlarged, nodular thyroid without speciﬁcity as to the pathology,
but with a differential diagnosis including thyroid carcinoma
which is present in 5–15% of cases123. It is a manifestation in
several syndromes and is common in areas with a high prevalence
of iodine deﬁciency. In those regions with adequate iodine
sources and MNG, it has been suggested that an underlying
genetic susceptibility may exist, and two speciﬁc loci have been
identiﬁed for familial MNG, one on chromosome 14q (DICER1 on
14q32.13)124 and the other on Xp22125. Shortly after the
identiﬁcation of germline mutations in DICER1 in PPB families, 5
families (53 individuals) with familial MNG were tested and three
of the 5 families also had a familial history of OSLCT whereas
the other two had only MNG126. Germline DICER1 mutations were
identiﬁed in 37 individuals showing a direct linkage of DICER1
mutations and MNG, and notably familial MNG and OSLCT were
independent of the occurrence of PPB126. A subsequent study
identiﬁed 12 distinct DICER1 hot spot mutations, all affecting the
metal-iron binding residues in 10 patients with germline DICER1
mutations127. Another study of 145 DICER1 carriers and 135 family
controls found a signiﬁcantly higher cumulative incidence of MNG
in the DICER1 carriers independent of gender128. It has been
shown that 3 of 4 and 1 of 6 DICER1 carrier women and men
develop MNG, respectively; MNG is estimated to have a 10–20%
penetrance in DICER1 carriers128,129. DICER1 carriers have a 16- to
24-fold increased risk of developing thyroid carcinoma which is
thought to be due to biallelic mutations in DICER1 leading to an
increase prevalence of benign thyroid nodules which over time
acquire additional genetic alterations with malignant progression128. The latter theme is likely relevant to the tumor
progression in type I PPB and pCN and other less well-studied
DICER1-associated neoplasms.
Differentiated thyroid carcinoma (DTC)
It is well established that exposure to radiation and high-dose
chemotherapy is associated with an increased risk for the
development for DTC130,131. Not surprisingly DTC has been
reported in two children who received radiation therapy in the
treatment of their PPBs132,133. At the time of those reports it was
not clear whether the DTCs were a consequence of radiation
exposure or a possible genetic linkage. A subsequent case of DTC
was reported in a child with a history of PPB who developed
recurrent disease and received salvage chemotherapy followed by
high-dose chemotherapy and hematopoietic stem cell transplantation, but no radiation134.
A direct association between DTC and PPB, speciﬁcally involving
DICER1 mutations, was initially suggested in a report of three
patients with a history of PPB; one developed MNG129, and was
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Fig. 15 Poorly differentiated thyroid carcinoma in a 22-year-old female with a past history of Wilms tumor at age 7 years and a
peritoneal sarcoma with cystic and rhabdomyosarcoma at age 11 years who was a DICER1 heterozygous germline variant. A The 3.5 cm,
tan-pink, encapsulated mass showing tumor in the capsule and closely apposed small nests of uniforms tumor cells with dense nuclei and
pale cytoplasm. B Trabecular and small follicular proﬁles of basophilic tumor cells demonstrating scattered mitotic ﬁgures.

subsequently diagnosed with an invasive follicular variant
papillary thyroid carcinoma (PTC)134. The second child had a type
I PPB, developed a ciliary body medulloepithelioma at 6 years of
age135, and one-year later was diagnosed with a follicular variant
PTC; the third patient had a history of PPB and pCN and at 11.5
years was found to have a PTC129. All of these patients had a
pathogenic germline DICER1 mutation and an acquired somatic
DICER1 mutation affecting the RNase IIIb domain123. One caveat in
these cases is that each patient received chemotherapy after the
diagnosis of PPB and that the latter mutagenic event could
explain the devolvement of DTC. However, a subsequent study
reported a DICER1 family with MNG; two patients in this kindred,
12- and 14-years old females, presented with MNG whose
thyroidectomies showed a PTC; one of these patients subsequently developed a pCN and virilization secondary to an
OSLCT136. Additionally, the mother and a sibling also developed
DTC; this report served to document that DTC occurs in DICER1
carriers without prior radiation and/or chemotherapy136.
Familial-syndromic PTC is reported in 10–14% of cases and in
some of these cases, there is a germline mutation as in familial
adenomatous polyposis, Cowden syndrome, Carney complex and
DICER1 syndrome137,138.
Follicular carcinoma (FC) in children is considerably less
common than PTC, representing less than 2% of all DTCs in
childhood; it is thought to be genetically different from FCs in
adults with their H/K/NRAS variants and PAX8-PPARy fusions139–141.
However, the incidence of these mutations has been largely
unknown in the pediatric population until the study of 15 children
with FC; a somatic DICER1 mutation was present in 8 patients
(53%) with mutated RNase IIIb domain in addition to germline
mutations in four patients142. Coexistent nodular hyperplasia and
follicular adenoma were signiﬁcantly more frequent in DICER1mutated FC compared to those without the mutation; another
observation was that all cases of FC in children less than 10-years
of age at diagnosis had a DICER1 mutation142. Any newly
diagnosed FC in a child under the age of 10 years should be
evaluated for a DICER1 mutation. In terms of prognosis none of the
FCs in children showed evidence of recurrence over a median
follow-up of 8.1 years but extensive capsular extension was only
seen in cases with a DICER1 mutation142.
FC and PTC in the pediatric population are clinically and
genetically distinct from PTC in adults. Although associated with a
high rate of regional lymph node metastasis, PTC in children has
an excellent survival with a 30-year disease free survival of
99–100%143. In a study of 40 consecutive thyroidectomy specimens from children, DICER1 mutations were identiﬁed in 3 (10%)
of 30 PTC, two of 10 benign thyroid nodules were found to have a
germline DICER1 mutation and an additional somatic mutation
within the RNase IIIb domain144.
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Of note, DICER1 mutations in DTC exclusive of DICER1 carriers is
rare with a somatic mutation frequency of approximately 0.6% (3
of 507 cases from the Cancer Genome Atlas Research Network
[accessed on 12/15/2020]), and when present should raise
concern about an undetected germline DICER1 mutation145.
However, as noted above in the pediatric population this
frequency is signiﬁcantly higher and thus a recommendation for
screening for DICER1 mutations in pediatric DTC is warranted.
Given this increased risk for the development of DTC, it is
recommended that a thyroid ultrasound around 8-years of age in
DICER1 carriers and then every 2 to 3 years, and in patients
receiving chemotherapy, a baseline ultrasound is recommended
and then annually for 5 years32.
Unlike many of the tumors associated with DICER1 mutations,
the pathology of the hyperplastic nodules and DTC has not
been correlated with any speciﬁc histologic features which
distinguishes them from the non-DICER1 counterpart. It is
important to question the possibility of a DICER1 germline
carrier in any case of nodular hyperplasia or DTC especially in a
patient 40 years old or less. A more compelling case for a
DICER1 mutation is the child with a poorly-differentiated thyroid
carcinoma which is discussed below.
Poorly-differentiated thyroid carcinoma. Poorly-differentiated
thyroid carcinoma (PDTC) is a rare neoplasm representing less
than 1% of all thyroid malignancies and has a 60–70% 10-year
survival146,147. PDTC in children is exceedingly rare and is usually
documented as case reports before the implementation of the
Turin criteria for the diagnosis of PDTC147. In a study by Chernock
et al148, six cases of PDTC using the Turin criteria in patients less
than 21-years old (age range: 14 to 19 years) were identiﬁed, of
which 5 cases (83%) had somatic DICER1 mutations, all encoding
the metal-ion binding sites of RNase IIIb domain; these 5 cases had
whole-exome sequencing and one germline pathogenic DICER1
mutation and one loss of heterozygosity for DICER1 were
identiﬁed. Three of ﬁve patients with follow-up information died
of disease, 8–24 months after diagnosis; all tumor-associated
deaths were those cases with lymphovascular invasion, extrathyroidal invasion and a positive resection margin148. A recent case in
a 22-year-old female with a DICER1 germline variant and two
previous DICER1-associated neoplasms showed extensive capsular
and vascular invasion and multiple foci of tumor and nodular
hyperplasia in the resected thyroid (Fig. 15).
Cervical-thyroid teratoma
Teratomas arising in the thyroid and/or neck account for 1% or
less of all extragonadal germ cell tumors; one of the larger case
series consisted of 30 cases with a mean age of 12.4 years (range:
newborn to 56-years)149. Those tumors in children, especially
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Fig. 16 Nasal chondromesenchymal hamartoma. A This tumor demonstrating a well-differentiated nodule of cartilage with an
accompanying spindle cell stroma without rhabdomyoblastic features. B Another example with a less cellular myxoid stroma and
cartilaginous nodules with variation in differentiation.

infants, were largely immature teratomas presenting at or soon
after birth150,151. Unlike gonadal teratomas, these tumors lacked
12q alterations152–154. Rooper et al. reported that four malignant
teratomas of the thyroid, unlike the mature and immature types,
had somatic hotspot DICER1 mutations155. Additionally, three of
four non-malignant cases had non-hotspot DICER1 mutations in
the latter study, but germline mutations were not identiﬁed in
these cases, likely representing sporadic mutations. All cases with
hotspot DICER1 mutations showed primitive and undifferentiated
elements, spindle cells with rhabdomyoblastic differentiation and
epithelial proliferation, and in three cases immature cartilage was
also identiﬁed155; these cases have a resemblance to the
previously discussed presacral malignant teratoid neoplasms. It
is unclear at this time whether there is an association between
DICER1 mutated thyroid teratomas and DICER1 predisposition
tumor syndrome since to our knowledge no cases of cervicothyroidal teratomas have been reported in DICER1 kindreds or in
association with other DICER1 related tumors in the experience of
the IPPBR. Yet another primitive multipatterned neoplasm of the
thyroid with DICER1 alterations has been reported, apparently
distinct from a teratoma, as a “malignant teratoid tumor” or
“thyroblastoma” which is likely the same tumor type that Rooper
and associates described155,156.
Nasal chondromesenchymal hamartoma (NCMH)
NCMH is a benign polypoid mesenchymal tumor arising in the
nasal cavity and/or paranasal sinuses whose microscopic features
have some resemblance to the chest wall hamartoma of
infancy157. The majority of cases in the original report presented
in infants under 3 months of age (6 of 7 cases), but subsequent
reports have documented a broader age range into adulthood157–
161
. A mass in the nasal cavity with extension to the paranasal
sinuses, especially to the ethmoid sinus is the clinical
presentation157,161. A cellular, somewhat immature mesenchyme
without rhabdomyoblastic differentiation accompanies and surrounds irregular islands of mature appearing hyaline cartilage
without atypical features; there is commonly a sharp interface
between the chondroid nodules and the cellular to myxoid stroma
(Fig. 16A, B). The myxoid stroma is composed of bland appearing
slender spindle cells with hypo- or hypercellular features which
may suggest RMS. In some cases, the more cellular stroma can
have a storiform pattern157,161. Other features are osteoclast-like
giant cell and blood-ﬁlled lake spaces with a resemblance to an
aneurysmal bone cyst147.

There was a single child in the initial report with a history of PPB
and it was suggested at the time that other neoplasms may
develop in these patients before the known linkage with
DICER1157. Almost ten-years later NCMH was reported in a 15year-old girl with a clinical history of congenital phthisis bulbi,
OSCST and PPB162. Subsequently, four cases of NCMH from
approximately 625 children with PPB were identiﬁed from the
IPPBR; this subset of cases ranged in age from 7 to 15 years161.
Notably three of these children were part of the exploratory
genetic project which established the initial associations of PPB
with DICER1 mutations9; nine additional cases from the IPPBR with
a history of PPB subsequently developed a NCMH (age range:
6–27 years)163. Among 8 patients tested for a DICER1 germline
mutation, it was identiﬁed in 6, and in two a somatic DICER1
missense mutation was detected in the NCMH providing
compelling evidence of an association with the DICER1 family of
tumors.
In total the IPPBR has identiﬁed 13 cases of NCMH, 7 females
and 6 males, with a mean age of 13 years (range: 6–27 years)
which is substantially older than the mean age at presentation in
the original report, 58 weeks (range: 5 days – 7 years) (p < 0.001).
Of note the patient in the original series with a history of PPB was
7-years old157.
A thought-provoking observation is the description in the
original report of case #7 of a predominant polypoid mass
composed almost exclusively of islands of cartilage and a loose
myxoid stroma with an epithelial lined cyst157. In the subsequent
IPPBR case series reporting the association with DICER1, all cases
had variably-sized cysts lined by respiratory epithelium161. This
morphologic association of cystic structures with a myxoid stroma
and accompanying islands of cartilage follows the histologic motif
of the other DICER1-associated neoplasms. To date, there have
been no observed examples of sarcomatous progression of
DICER1-associated NCMHs though these tumors may locally recur
and directly invade into the cranial space157.
CENTRAL NERVOUS SYSTEM AND EYE
The central nervous system including the eye as a direct
appendage of the brain is the site of primary DICER1-associated
tumors while the brain is the most common metastatic site of
PPB164. Primary DICER1-associated neoplasms affecting the
central nervous system and eye include the following tumor
types: ciliary body medulloepithelioma (CBME), pituitary
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blastoma, pineoblastoma, primary DICER1-associated sarcoma
and embryonal tumor with multilayered rosettes. Kock et al.
have provided a comprehensive review of the DICER1 CNS
manifestations165.
Eye
Kaneko et al. demonstrated that DICER1 levels are decreased in
the retinal pigmented epithelium (RPE) in cases of extensive agerelated macular degeneration, and showed in DICER1 knockdown
models that an increased accumulation of Alu RNA in RPE cells
resulted in RPE degeneration166. Given this direct causality of
DICER1 and blindness, it was questioned arose whether individuals
with germline DICER1 mutations are predisposed to visual loss;
this inquiry was addressed in a comprehensive family-based study
in 103 patients with a pathogenic germline DICER1 mutation and
69 family control subjects167. All subjects underwent an ophthalmic evaluation, with a mean age of 27 years and 37.9 years for the
DICER1 and control groups, respectively. Ocular abnormalities
were more commonly seen in the DICER1 group (22% vs 6%, p =
0.005) with the most common alterations involving the optic
nerve, retinal pigmentary abnormalities, macular degeneration
and an epiretinal membrane167. Regarding the visual acuity, most
of those in the DICER1 group had an acuity greater than 20/40 in
both eyes. Notably during the study evaluation, ciliary body
medulloepithelioma was identiﬁed in patients in the DICER1 group
within 1 year of the dilated eye examination. A recommendation
has been made for an annual dilated ophthalmic examination in
DICER1 carriers, especially in those patients under the age of 10
years167.
Ciliary body medulloepithelioma (CBME). CBME is the most
common congenital and early childhood tumor of the nonpigmented epithelium of the ciliary body168,169. This primitive
neuroepithelial neoplasm has been classiﬁed into nonteratoid
and teratoid types, which is based on the absence or presence of
heterologous elements including cartilage, rhabdomyoblasts and
neuroglia169–172. Cystic or multicystic component is recognized in
both the teratoid and non-teratoid CBME; both types behave in a
benign or malignant manner correlating with the presence of
poorly differentiated neuroepithelial proﬁles with or without
rosettes, chondrosarcomatous and/or rhabdomyosarcomatous
foci, and invasion of the uvea, cornea or sclera with or without
extrascleral extension168,170,172. This composite of histologic
features is another example of the common morphologic motif
of several other pulmonary and extrapulmonary DICER1-associated neoplasms.
Four cases of CBME were identiﬁed among 299 enrolled PPB
cases; three occurred in patients with PPB and another in the
father of children with PPBs135. This observation was followed by a
case report of 9-year-old girl with a CBME and history of PPB173.
Additionally, Kaliki et al. reported a history of PPB in 2 patients
among 41 cases of CBME168. Although there is a clear association
of this rare ocular neoplasm with PPB and with DICER1 syndrome,
only one patient in these reports had germline and a somatic
DICER1 testing performed with a paternally inherited germline
DICER1 mutation135. The other study to our knowledge with
genetic testing was an 18-year-old woman who presented with a
2-month history of painless visual loss and was found to have a 6
mm ciliary body mass; the tumor was characterized by a
proliferation of neurotubular structures and cords surrounded by
a loose stroma without heterotopic features and a somatic DICER1
mutation was identiﬁed in this case in exon 26 (D1709N) without a
germline mutation174.
Brain
Pituitary blastoma. Pituitary blastoma is a neoplasm presenting
in children under 2-years of age in the pituitary gland whose
histologic features include primitive blastemal cells, glandular-like
Modern Pathology (2022) 35:4 – 22

structures composed of small cells resembling Rathke epithelium
and large secretory cells175,176. A total of 14 cases to date have
been evaluated for DICER1 mutations, and 11 (79%) have
pathogenic heterozygous germline DICER1 mutations and in
the remaining three without a germline mutation, a somatic
DICER1 mutation involving the RNase IIIb domain was
identiﬁed165,177. The diagnosis of a pituitary blastoma is an
indication for germline DICER1 testing.
Pineoblastoma. Pineoblastoma, another rare primitive neoplasm
of the CNS, typically presenting in children to young adults; this
tumor has been associated with germline RB1 mutations in the
setting of the so-called trilateral retinoblastoma178. This highgrade hypercellular neoplasm is composed of primitive small cells
with occasional rosettes; the histologic pattern is shared by other
primitive tumors in the CNS such as medulloblastoma and atypical
teratoid/rhabdoid tumor so that location and imaging ﬁndings are
important considerations in the diagnosis. When these tumors
occur in those with germline DICER1 mutations, there is commonly
loss of heterozygosity of the wild-type DICER1 allele which is
contrary to the other DICER1-associated neoplasms in which
the “second-hits” are somatic missense RNase IIIb hotspot
mutations165,179,180.
Primary DICER1-associated central nervous system sarcoma
Several examples of primary CNS neoplasms have been reported
with histologic features similar to other DICER1-associated
neoplasms including PPB79,165,181–185. One large case series
consisted of 22 intracranial sarcomas of which 21 (95%) had
DICER1 hotspot mutations as well as TP53 mutations in 50% of
cases; germline testing was only performed on ﬁve cases of which
two had a germline DICER1 mutation183. Most of these tumors
were supratentorial in location with only two infratentorially
examples, one in the cerebellopontine angle and the other in the
cerebellum. Another cohort of these tumors was reported by
Kamihara et al; six patients from 3- to 15-years of age presented
with a supratentorial tumor, all of which had one inactivating
DICER1 mutation and one hotspot mutation in the RNase IIIb
domain182.
Many of these tumors have had a morphologic resemblance to
type II/III PPB with areas ranging from solid to cystic foci and
primitive malignant spindle cells with diffuse anaplasia, focal
rhabdomyoblastic differentiation, primitive embryonal-type foci in
some cases and less commonly chondroid differentiation. Given
the overlapping features with PPB in a neoplasm in the CNS, a
review of the imaging, including the chest, is necessary to rule out
the possibility of metastatic PPB; however, most primary DICER1associated sarcomas are located supratentorial whereas metastatic
PPB tends to occur in the cerebellum25. We have seen metastatic
PPB to the CNS develop shortly after the diagnosis of PPB, but
have not seen a child with a PPB initially present with a brain
metastasis.
Embryonal tumor with multilayered rosettes (ETMR)-like
cerebellar tumor
Two cerebellar tumors have been seen in an 8- and 11-month
old girls; both tumors had features of an embryonal type
neoplasm with multilayered rosettes with abundant neuropil
and true rosettes; one of the cases in the 8-month-old girl
additionally had chondroid differentiation186. Both tumors had
somatic hotspot DICER1 mutations, in addition to a germline
DICER1 nonsense pathogenic mutation. These two cases again
highlight the importance of the potential histologic clues to a
DICER1-associated neoplasm. The authors advised DICER1
testing in any embryonal or primitive appearing CNS tumor,
not otherwise speciﬁed186. An additional case presenting in a 2month-old girl has been reported; this tumor was composed of
primitive small cells in a background of neuropil and scattered
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multilayered rosettes and pseudo-rosettes, in addition to rare
rhabdomyoblasts165. A primitive CNS tumor, especially with
rhabdomyoblastic and/or chondroid differentiation, should
prompt DICER1 testing.
OTHER NON-NEOPLASTIC DICER1 ASSOCIATIONS
Macrocephaly
Macrocephaly is deﬁned as a head circumference greater than
97th percentile compared to the published general population. In
a cohort of 67 DICER1 carriers, 28 (42%) qualiﬁed as macrocephalic
and none had an occipital-frontal circumference below the 3rd
percentile which was signiﬁcantly higher when compared to a
cohort of 43 family controls of which only 12% were macrocephalic187. Additionally, this study revealed that DICER1 carriers
were taller than family controls after controlling for gender. These
non-neoplastic overgrowth manifestations in combination with
other ﬁndings as discussed in this review could facilitate the
identiﬁcation of suspected DICER1 carriers.
Dental abnormalities
Prior studies have shown that knockout DICER1 models results in
various tooth abnormalities since miRNAs have a crucial role in
tooth epithelial stem cell differentiation188–190. It was then
hypothesized that DICER1 carriers may present with a spectrum
of dental abnormalities and was tested in 57 DICER1 carriers and
55 family controls191. Some signiﬁcant differences included an
excess of crown bulbousness, taurodontism and periodontitis in
the DICER1 carriers188. Although not statistically signiﬁcant,
supernumerary teeth, enamel defects and abnormal molar
morphology were more common in the DICER1 carriers.
Global developmental delay, lung cyst, overgrowth and Wilms
tumor (GLOW syndrome)
GLOW is an acronym for global developmental delay, lung cyst,
overgrowth and Wilms tumor as a syndrome association192. Two
patients, a 9-month-old boy and a 14-month-old boy, had
development milestone delay, height and weight greater than
75th percentile, head circumference greater than 98th percentile,
nephromegaly with Wilms tumor, lung cysts and dysmorphic
features including hypertelorism, ﬂat nasal bridge and frontal
bossing. A heterozygous DICER1 de-novo mutation was identiﬁed
in one case, and a DICER1 missense mutation in the other child;
these mutations were present in varying frequencies in the
available tissues for testing. These ﬁndings suggest that in
addition to its oncogenic role, DICER1 has any number of other
gene functions including growth signaling pathways as in the case
of DICER1-associated macrocephaly.
COMMENTARY/CONCLUSION
Cancer predisposition syndromes (CPS) with their germline
mutations have come to occupy a increasingly central role in
our understanding in the development of tumors in all age
groups. One of the earliest CPS was recognized in the setting of
retinoblastoma which served as the basis of the Knudson two-hit
hypothesis of the tumor suppressor gene with biallelic loss of RBI
gene193,194. With the loss of both copies, additional genetic and
epigenomic events facilitated tumor progression of retinoblastoma195. Several of these CPS were well-documented in children
before whole exonic and genomic sequencing became available
through classic kindred analysis as in the cases of neuroﬁbromatosis types I and 2, familial adenomatous polyposis, Li-Fraumeni
syndrome (LFS) and multiple endocrine neoplasia types 1 and 2. It
is currently estimated that 10% of solid tumors in children are
manifestations of a recognized CPS; however, one study from
Denmark concluded that the frequency of a germline pathogenic
mutations may approach 50%196.

DICER1 syndrome (DICER1 tumor predisposition syndrome) is
one of more recently recognized CPS in childhood whose
germline mutation, a heterozygous DICER1 mutation, was ﬁrst
recognized just over 16 years ago9. The initial event in the
evolution of the DICER1 syndrome was the report of a seemingly
unique, as yet not fully characterized primary neoplasm of the
lung and/or chest wall in children, which was designated a PPB to
differentiate it from the adult pulmonary blastoma16. After ﬁrst
report, subsequent cases pointed to a possible familial predisposition and that other extrapulmonary neoplasms occurred in
children with PPB and within affected kindreds17. A solid,
multipatterned primitive sarcoma was the characteristic pathologic feature of this neoplasm from the report of the ﬁrst 11 cases16,
but it subsequently became apparent that this solid neoplasm was
the ultimate stage in a lesion which began as a circumscribed,
multiloculated cyst in the lung which was regarded at one time as
a type 4 congenital pulmonary airway (adenomatoid) malformation. Beneath the epithelial lining of the cysts in many of these
lesions, primitive small cell population with and without
rhabdomyoblastic differentiation and small nodules of immature
cartilage were present in the reconceptualized type I PPB23.
Proliferation of these neoplastic cells eventuated in progressive
overgrowth of the cysts with the formation of a mass with or
without residual cystic foci (type II or type III PPB). This evolution
from a multiloculated cyst to a solid tumor with the pathologic
features of the ﬁrst 11 cases was correlated with the median age
at diagnosis (cystic or type I PPB at 8 months and the solid type III
PPB at 41 months), and a 5-year OS of 91% to 53% with
progression to the solid, aggressive type III PPB25. These
observations were the basis of the argument that the PPB
underwent tumor progression from a cystic lesion to a solid high
grade neoplasm with its prognostic consequences.
CPS are deﬁned by their canonical germline mutations, but also
by the phenotype(s) of their associated neoplasms197. Each of the
mutated genes with the end result of a clinical malignancy of one
type or another has set molecular perturbations such as
disordered genomic stability and cell cycle dysregulation as in
the case of LFS [TP53] or miRNA processing in the DICER1
syndrome198,199. In the DICER1 syndrome, the spectrum of tumor
types has expanded as well as our understanding of DICER1 in
tumorigenesis (Table 1). It is the clinical and pathologic
manifestations of the DICER1 syndrome which is the focus of this
review. It was appreciated in the early stage of our studies that
PPB was probably not the sole manifestation of an as undeﬁned
syndrome.
In addition to a discussion of the various DICER1-associated
tumors, the other point of emphasis is the morphologic similarity
of several of these neoplasms which reﬂects a common
pathogenetic and possibly histogenetic pathway whose pathologic features overlap with those of PPB (Table 1). Some of these
tumor are predominantly cystic in their early stage of evolution,
possibly as a manifestation of defective branching morphogenesis, a key developmental role of DICER119,21. Both the lung and
kidney rely upon branching morphogenesis for normal development19–21. In fact, normal development, ostensibly normal with
one germline copy of non-mutated DICER1, sets the stage for the
potential consequences with the somatic loss of the second copy
in the two-hit model200. In the case of the tumorigenesis pathway,
the second somatic hit and its particular anatomic site determine
where the primary DICER1-associated neoplasm(s) presents in one
or more organs or elsewhere. Additional mutations, such as in
TP53 and other as yet unidentiﬁed genomic or epigenomic
events32, facilitate the progression to a DICER1-associated
neoplasm with one or multiple morphologic patterns in a complex
collage of rhabdomyoblasts with features of ERMS, spindle cells,
blastemal islands with or without rhabdomyoblastic differentiation, nodules of cartilage with fetal or immature or sarcomatous
features and a population of larger, pleomorphic cells with or
Modern Pathology (2022) 35:4 – 22
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without anaplasia in selected tumor types. Another feature is the
presence of immature tubules resembling primitive tubules with
neural or nephrogenic features are seen in those DICER1associated neoplasms with teratoid features which together with
the other differentiated sarcomatous components may suggest or
lead to the diagnosis of a germ cell neoplasm; these latter ﬁndings
have been seen in the eye, thyroid, cervix, central nervous system
and pre-sacral region. There is a set of pathologic features in the
various DICER1 neoplasms that should set in motion a consideration whether the patient may have a DICER1 heterozygous
germline mutation.
As a ﬁnal note, there are some interesting parallels between the
DICER1 tumor syndrome and LFS as compared to some of the
other inherited tumor predisposition syndromes whose tumor
types are conﬁned to a limited number of sites and tumor types.
LFS is characterized by ﬁve core tumor types accounting for 75%
of all neoplasms including carcinoma of the breast (25–30% of
cases), soft tissue sarcomas (~15%), brain tumors (13–15%),
adrenocortical carcinoma (10%) and osteosarcoma (10%). Likewise, the tumors of the DICER1 tumor syndrome are found in a
number of organ systems as discussed in this overview and are as
diverse as the pineoblastoma to the PDTC, but unlike LFS there is
some unity to the morphologic pattern which is predominantly
sarcomatous and centered around ERMS with a cambium layer of
rhabdomyoblasts beneath an epithelia appropriate to the
anatomic site or a more diffuse solid pattern, often intermixed
with non-RMS areas, cartilage and anaplasia; these features in
some combination are maintained to some extent throughout the
spectrum of DICER1-associated neoplasms with a few exception.
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